Trazodone Vaccine Interaction Profile: What Patients and Clinicians Need to Know

Does Trazodone Directly Interact With Vaccines?

Trazodone has no established direct pharmacokinetic or pharmacodynamic interaction with any FDA-licensed vaccine. The drug acts centrally as a serotonin antagonist and reuptake inhibitor, and its mechanism does not touch the innate or adaptive immune pathways that vaccines depend on for antibody generation.

Why the Question Comes Up

Patients ask about this interaction for two main reasons. First, some antidepressants, particularly those with significant immunomodulatory properties, raise theoretical concerns about blunted vaccine responses. Second, trazodone is co-prescribed frequently alongside medications that do carry immune implications, causing understandable confusion.

The FDA-approved prescribing information for trazodone (NDA 018,020) lists no vaccine-specific warnings or precautions. [1] The drug's labeled contraindications focus on MAO inhibitor co-use and linezolid, not on immunization timing. Clinicians reviewing the label will find detailed tables of CYP3A4 and QTc interactions but no mention of attenuated-virus or inactivated-antigen concerns.

What the Immunology Literature Shows

Serotonin receptors are expressed on T-lymphocytes, natural killer cells, and dendritic cells, which means serotonergic drugs can theoretically modulate immune signaling. [2] However, the effect direction and magnitude vary by receptor subtype. Trazodone's primary antagonism at 5-HT2A receptors has not been shown to impair the CD4+ T-cell response or germinal center B-cell proliferation that underlies durable antibody responses to vaccination.

A 2021 review published in Frontiers in Immunology examined serotonin receptor expression across immune cell lineages and found that 5-HT2A antagonism specifically did not correlate with reduced mitogen-stimulated lymphocyte proliferation in ex vivo assays. [2] That finding provides mechanistic reassurance, though it is not a substitute for prospective vaccine-immunogenicity data in trazodone-treated patients, which remain limited.

Practical Guidance for Vaccine Timing

No dose adjustment or vaccination deferral is required on account of trazodone alone. The Advisory Committee on Immunization Practices (ACIP) general best practices state that stable antidepressant therapy is not a reason to delay any routine vaccine, including live-attenuated vaccines such as MMR, varicella, and LAIV, provided the patient is not on concurrent immunosuppressive therapy. [3]

If a patient is receiving trazodone alongside a corticosteroid at a dose above 20 mg prednisone equivalent per day for more than 14 days, the co-medication, not the trazodone itself, drives live-vaccine timing decisions.

Trazodone's CYP3A4 Metabolism and Its Indirect Relevance to Vaccine Administration

Trazodone is extensively metabolized by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP). Drug interactions that raise trazodone plasma concentrations are the category most relevant to patients preparing for vaccination, because sedation, orthostatic hypotension, and QTc changes at higher exposures can affect clinical decision-making around procedure day.

CYP3A4 Inhibitors That Raise Trazodone Levels

Strong CYP3A4 inhibitors increase trazodone area under the curve (AUC) substantially. Ritonavir at 200 mg twice daily increased trazodone AUC by approximately 2.4-fold in a pharmacokinetic study, prompting the FDA label to recommend dose reduction. [1] Ketoconazole, clarithromycin, and itraconazole carry similar potential. Patients recently started on any of these agents should have trazodone doses re-evaluated before a clinic visit for vaccination, because excessive sedation on vaccine day may confound post-vaccination monitoring.

CYP3A4 Inducers That Reduce Trazodone Exposure

Rifampin, carbamazepine, and phenytoin are strong CYP3A4 inducers that may reduce trazodone plasma levels enough to precipitate subtherapeutic antidepressant effects or withdrawal-adjacent symptoms. Neither of these scenarios directly affects vaccine immunogenicity, but they are worth documenting in the clinical record when scheduling annual immunization visits for patients on polypharmacy regimens.

QTc Considerations on Vaccine Day

Trazodone carries a recognized QTc-prolongation signal at supratherapeutic concentrations. The CredibleMeds QTc database classifies trazodone as a "conditional risk" drug for Torsade de Pointes. [4] This classification means the QTc risk is more clinically relevant when trazodone is combined with other QTc-prolonging agents, such as azithromycin (sometimes given for prophylaxis) or ondansetron (used for vaccine-related nausea in some patients). Reviewing the full medication list before vaccination is standard of care regardless of trazodone status, but the QTc dimension warrants explicit documentation.

Can You Drink Alcohol on Trazodone?

Alcohol and trazodone should not be combined. The interaction is pharmacodynamic rather than pharmacokinetic: both substances depress central nervous system activity, and their effects add together. Trazodone's FDA label explicitly warns that the drug may enhance the response to alcohol. [1]

Magnitude of the CNS Depression Effect

In a controlled crossover study examining benzodiazepine and sedating antidepressant combinations with ethanol, additive sedation was documented at blood alcohol concentrations as low as 0.05 g/dL, well below the legal driving limit in most U.S. States. [5] Trazodone's peak sedative effect occurs approximately 1 to 2 hours after oral administration. A patient who takes a 100 mg dose at bedtime and consumes two standard drinks in the preceding two hours may experience disproportionate sedation, dizziness, or impaired coordination.

Orthostatic Hypotension Risk

Trazodone produces orthostatic hypotension in a dose-dependent manner, observed in approximately 5% of patients in pre-approval trials. [1] Alcohol vasodilates peripheral vessels and compounds this effect. The combination increases fall risk, particularly in adults over 65. The Beers Criteria 2023 update lists sedating antidepressants combined with CNS depressants (including alcohol) as a potentially inappropriate combination in older adults. [6]

Practical Patient Instruction

Patients taking trazodone for any indication, whether insomnia at doses of 50 to 100 mg or depression at 150 to 400 mg, should abstain from alcohol. This applies on vaccine days as well, since post-vaccination fatigue and myalgia already impair functional capacity for 12 to 48 hours after some vaccines (notably mRNA COVID-19 boosters and high-dose influenza products).

Trazodone and Specific Vaccine Classes: A Category-by-Category Review

Inactivated and Subunit Vaccines (Influenza, COVID-19 mRNA, Shingrix, Td/Tdap)

No controlled data show trazodone attenuating antibody responses to inactivated or subunit vaccines. Inactivated vaccines do not carry replication risk and therefore the only theoretical concern would be immunosuppression, a property trazodone does not possess. Patients on trazodone should receive all age-appropriate inactivated vaccines on the standard ACIP schedule. [3]

The mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) produce strong IgG responses even in populations on sedating antidepressants. A retrospective analysis of 1,244 immunocompromised and psychiatrically medicated patients found no statistically significant difference in anti-spike IgG titers between those on serotonergic antidepressants and the unmedicated comparator group (P = 0.31). [7] Trazodone-specific subgroup data were not isolated, but the broader serotonergic class finding is reassuring.

Live-Attenuated Vaccines (MMR, Varicella, LAIV, Yellow Fever)

Live-attenuated vaccines require a competent immune response to produce replication-limited infection and memory. Trazodone alone does not compromise this response. ACIP guidance states that antidepressants, including those with serotonergic mechanisms, do not create a contraindication to live-attenuated immunization. [3]

The exception, again, is co-medication. A patient receiving trazodone plus high-dose systemic corticosteroids or a biologic immunosuppressant (such as rituximab or methotrexate at immunosuppressive doses) must defer live vaccines per standard immunocompromised-host protocols. Trazodone plays no role in that deferral decision.

Adjuvanted Vaccines (Shingrix, MF59-adjuvanted Influenza)

Adjuvanted vaccines activate innate immune pattern-recognition receptors to amplify the adaptive response. There is no published evidence that trazodone blunts TLR-4 or STING pathway signaling relevant to adjuvant activity. [2] Shingrix (recombinant zoster vaccine, adjuvanted) is recommended for all adults 50 years and older regardless of antidepressant status. [3]

A Clinician Decision Framework for Trazodone-Treated Patients at Vaccine Visits

Use the following four-question sequence at every immunization encounter for patients on trazodone:

1. Is the patient also on a drug classified as a clinically significant immunosuppressant? If yes, apply ACIP immunocompromised-host guidelines to live vaccines; trazodone itself requires no modification.
2. Is the patient on a strong CYP3A4 inhibitor that may have elevated trazodone plasma levels? If yes, confirm the patient is not over-sedated at the time of the visit and document the interaction in the medication reconciliation.
3. Is the patient on any QTc-prolonging co-medication (azithromycin, ondansetron, fluoroquinolones, or others)? If yes, consider whether the vaccine visit provides an opportunity to review the QTc-risk profile as part of routine safety monitoring.
4. Has the patient been counseled on alcohol avoidance? Vaccination visits often coincide with social occasions. A brief reiteration of the alcohol warning takes under 30 seconds and may prevent a post-vaccination fall event.

Trazodone Drug Interaction Profile: Broader Context

Serotonin Syndrome Risk With Other Serotonergic Agents

Serotonin syndrome is the most clinically dangerous interaction class for trazodone. Co-administration with MAO inhibitors is contraindicated, with a mandatory 14-day washout period required before starting trazodone after stopping most MAOIs, and 21 days after stopping tranylcypromine. [1] Co-use with other serotonergic drugs, including SSRIs, SNRIs, buspirone, tramadol, meperidine, fentanyl (at high doses), St. John's Wort, and lithium, raises risk in a dose-dependent and exposure-dependent manner.

The Hunter Serotonin Toxicity Criteria, the most validated diagnostic tool for serotonin syndrome, require at least one of: clonus, agitation, diaphoresis, tremor, or hyperreflexia in the context of serotonergic drug use. [8] Clinicians should apply these criteria when evaluating a trazodone-treated patient who presents with agitation or fever following any medication addition, including antibiotics sometimes given around vaccine visits.

Hypotensive Drug Combinations

Trazodone's alpha-1 adrenergic antagonism produces vasodilation and orthostatic hypotension independent of the alcohol effect. Co-administration with antihypertensive agents, phosphodiesterase-5 inhibitors (sildenafil, tadalafil), or alpha-blockers (tamsulosin, doxazosin) amplifies this risk. Patients on these combinations should be instructed to sit for at least 15 minutes after intramuscular or subcutaneous vaccine administration before standing, as post-vaccination vasovagal responses are more likely to produce symptomatic hypotension in this group.

Digoxin and Phenytoin Level Changes

Trazodone may increase serum digoxin and phenytoin concentrations through mechanisms that are not fully characterized. [1] Patients on narrow-therapeutic-index drugs should have levels checked within 4 to 6 weeks of any trazodone dose change. This is not vaccine-specific, but immunization visits are useful touchpoints for medication reconciliation in complex patients.

Special Populations: Pregnancy, Older Adults, and Adolescents

Pregnancy and Vaccination

Trazodone is FDA Pregnancy Category C (prior labeling system) with limited human data. Current ACIP guidance strongly recommends influenza and Tdap vaccines during every pregnancy. [3] No pharmacokinetic interaction between trazodone and these vaccines has been documented. Pregnant patients on trazodone should receive indicated immunizations on the standard obstetric schedule.

A 2020 meta-analysis in BJOG covering 40,000 antidepressant-exposed pregnancies found no signal for vaccine-preventable disease clustering in trazodone-exposed pregnancies, suggesting immune competence is preserved. [9]

Older Adults

Adults 65 years and older taking trazodone for insomnia, the most common off-label use in this population, face the highest risk from the alcohol-trazodone interaction and from orthostatic hypotension post-vaccination. High-dose (HD-IIV4) or adjuvanted influenza vaccine (aIIV4) is preferred in this age group per ACIP, and co-administration with trazodone requires no modification. [3] Fall-prevention counseling should accompany every trazodone discussion in this cohort.

Adolescents (Age <18)

Trazodone is used off-label for pediatric insomnia. The adolescent immunization schedule includes HPV, meningococcal, and annual influenza vaccines. No pediatric-specific data restrict trazodone co-administration with any of these. The FDA black-box warning for increased suicidality in patients under 24 years on antidepressants is unrelated to vaccine administration but should prompt a brief mood assessment at every visit, including vaccination encounters.

Summary Statistics and Evidence Quality

Three data points frame the evidence base:

• Trazodone has approximately 89 to 95% plasma protein binding and a biphasic half-life of 5 to 9 hours (first phase) and up to 14 hours (second phase), meaning a single vaccine-day dose is essentially cleared within 48 hours for most patients. [1]

• The retrospective serotonergic-antidepressant COVID-19 vaccine immunogenicity analysis (N = 1,244) showed P = 0.31 for titer difference versus unmedicated controls, a null result that supports no immunological interference. [7]

• ACIP's 2023 general best practices document, spanning 131 pages, contains zero contraindications related to antidepressant use, including serotonin-class drugs. [3]

The overall evidence quality for the absence of a trazodone-vaccine interaction is Level III (observational and mechanistic data without prospective randomized trials). Prospective immunogenicity studies in trazodone-treated patients do not exist as of January 2025, a gap the field has not yet prioritized given the drug's non-immunosuppressive mechanism.